| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
4,258 |
3,898 |
$1.52M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,236 |
3,575 |
$1.28M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,367 |
2,928 |
$626K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
832 |
676 |
$346K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
177 |
156 |
$252K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
423 |
352 |
$121K |
| 71046 |
Radiologic examination, chest; 2 views |
1,305 |
1,092 |
$83K |
| 80061 |
Lipid panel |
6,454 |
5,992 |
$75K |
| 80053 |
Comprehensive metabolic panel |
7,774 |
6,881 |
$60K |
| 36415 |
Collection of venous blood by venipuncture |
22,977 |
19,609 |
$50K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
5,165 |
4,722 |
$42K |
| 80050 |
General health panel |
965 |
898 |
$41K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,673 |
1,479 |
$40K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,033 |
781 |
$39K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,185 |
838 |
$38K |
| 83880 |
|
1,503 |
1,295 |
$34K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
566 |
481 |
$32K |
| 71045 |
Radiologic examination, chest; single view |
534 |
452 |
$31K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,425 |
4,746 |
$30K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
27 |
27 |
$26K |
| 87581 |
|
944 |
780 |
$25K |
| 87486 |
|
949 |
782 |
$25K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,015 |
875 |
$23K |
| 83735 |
|
3,457 |
3,112 |
$19K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
991 |
909 |
$14K |
| 70450 |
Computed tomography, head or brain; without contrast material |
29 |
25 |
$14K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,871 |
1,705 |
$13K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
421 |
356 |
$13K |
| 85027 |
|
2,315 |
2,096 |
$12K |
| 70210 |
|
219 |
171 |
$12K |
| 81001 |
|
4,564 |
4,004 |
$11K |
| 80164 |
|
857 |
758 |
$10K |
| 80305 |
|
1,095 |
951 |
$10K |
| 95800 |
|
17 |
14 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
182 |
121 |
$9K |
| 84484 |
|
1,257 |
959 |
$9K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
79 |
77 |
$8K |
| 83605 |
|
975 |
836 |
$7K |
| 82553 |
|
1,251 |
947 |
$7K |
| 82607 |
|
550 |
497 |
$7K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
47 |
38 |
$6K |
| 82746 |
|
451 |
403 |
$5K |
| 82550 |
|
1,273 |
979 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
355 |
339 |
$5K |
| 82728 |
|
172 |
166 |
$2K |
| 81025 |
|
232 |
213 |
$2K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
13 |
12 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
17 |
13 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41 |
41 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41 |
41 |
$1K |
| 82150 |
|
347 |
283 |
$1K |
| 84439 |
|
187 |
163 |
$1K |
| 83540 |
|
171 |
166 |
$1K |
| 83690 |
|
210 |
188 |
$984.65 |
| 81015 |
|
323 |
297 |
$861.01 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
32 |
25 |
$837.32 |
| 80183 |
|
85 |
64 |
$775.97 |
| 0002A |
|
38 |
21 |
$741.60 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
69 |
50 |
$681.57 |
| 85730 |
|
221 |
160 |
$595.51 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
78 |
73 |
$543.91 |
| 81003 |
|
215 |
200 |
$449.68 |
| 85610 |
|
221 |
161 |
$414.99 |
| 0001A |
|
39 |
21 |
$302.38 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
12 |
12 |
$288.96 |
| 84100 |
|
92 |
71 |
$231.76 |
| 87070 |
|
18 |
17 |
$210.96 |
| 82947 |
|
80 |
73 |
$186.16 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12 |
12 |
$134.83 |
| 85379 |
|
22 |
12 |
$90.48 |
| 86701 |
|
12 |
12 |
$88.90 |
| 84450 |
|
13 |
13 |
$62.16 |
| 80076 |
|
12 |
12 |
$57.19 |
| 85652 |
|
31 |
25 |
$54.00 |
| J2704 |
Injection, propofol, 10 mg |
86 |
42 |
$0.00 |
| 00000 |
|
13 |
12 |
$0.00 |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
13,455 |
911 |
$0.00 |
| 91300 |
|
47 |
21 |
$0.00 |
| 87631 |
|
12 |
12 |
$0.00 |